GlaxoSmithKline plc Capital Reinvestment Ratio
GlaxoSmithKline plc capital reinvestment ratio. GlaxoSmithKline plc (GSKN) has a Capital Reinvestment Ratio of 0.40x as of September 2025, meaning it reinvests 0% of its operating cash flow (MX$2.22 Billion) in capital expenditures (MX$879.00 Million). See GSKN FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of GlaxoSmithKline plc (2013–2024)
Capital reinvestment ratio of GlaxoSmithKline plc from 2013 to 2024. This chart tracks GlaxoSmithKline plc's Capital Reinvestment Ratio across 12 annual periods. See GlaxoSmithKline plc leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
GlaxoSmithKline plc Capital Reinvestment Ratio by Year (2013–2024)
GlaxoSmithKline plc capital reinvestment ratio by year from 2013 to 2024. For the full cash flow conversion analysis, see GSKN cash flow metrics.
| Year | Reinvestment Ratio | Operating CF (MXN) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.45x | MX$6.55 Billion | MX$2.98 Billion | ▲ +7.8% |
| 2023 | 0.42x | MX$5.48 Billion | MX$2.31 Billion | ▲ +173.4% |
| 2022 | 0.15x | MX$7.40 Billion | MX$1.14 Billion | ▲ +29.2% |
| 2021 | 0.12x | MX$7.95 Billion | MX$950.00 Million | ▲ +2.0% |
| 2020 | 0.12x | MX$8.44 Billion | MX$989.00 Million | ▼ -25.7% |
| 2019 | 0.16x | MX$8.02 Billion | MX$1.26 Billion | ▼ -1.2% |
| 2018 | 0.16x | MX$8.42 Billion | MX$1.34 Billion | ▼ -28.5% |
| 2017 | 0.22x | MX$6.92 Billion | MX$1.54 Billion | ▼ -38.3% |
| 2016 | 0.36x | MX$6.50 Billion | MX$2.35 Billion | ▼ -32.6% |
| 2015 | 0.54x | MX$2.57 Billion | MX$1.38 Billion | ▲ +134.0% |
| 2014 | 0.23x | MX$5.18 Billion | MX$1.19 Billion | ▲ +39.5% |
| 2013 | 0.16x | MX$7.22 Billion | MX$1.19 Billion | — |